arrow
K

Karine Le Malicot

assistance publique hopitaux paris
H指数:30
被引数:3,237

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Fluoropyrimidine- versus Gemcitabine-Based Chemotherapy for Metastatic Recurrence After Resection of Ampullary Adenocarcinoma: a Real-World Analysis of the FFCD-AC Cohort

壶腹腺癌切除术后转移性复发的氟嘧啶类与吉西他滨为基础的化疗比较:FFCD-AC队列的真实世界分析

2026-10-090
OAAI
Interpretable AIto predict anal cancer local failure at 3 years with the FFCD Anabase prospective multicentric cohort

可解释AI预测FFCD Anabase前瞻性多中心队列中3年肛门癌局部复发

2026-08-010
PRE
Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.

预测老年结直肠癌患者严重毒性和死亡率:3项临床试验和3项前瞻性队列分析

2026-07-120
OA
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma

FRUQUITAS试验:三氟尿idine/替匹拉西布联合/不联合 fruquintinib治疗经治转移性胃食管腺癌的ENGIC协作组随机III期研究设计

2026-05-090
OAAI
Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus – An ancillary study of the FFCD0904 phase I and II trial

局部肛管鳞状细胞癌治疗中体成分与帕尼单抗药代动力学关系分析——FFCD0904 I/II期试验的辅助研究

2026-03-210
OAAI
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: an individual patient data meta-analysis

可切除或已切除结直肠癌肝转移患者的系统性化疗:一项个体患者数据Meta分析

2025-11-010
PRE
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

Nal-IRI/LV5-FU 与紫杉醇作为转移性食管鳞状细胞癌患者二线治疗的比较(PRODIGE 62-FFCD 1701-OESIRI)

2025-08-220
OAAI
Salvage abdominoperineal resection for anal squamous cell carcinoma after radiotherapy or chemoradiotherapy: analysis of the French prospective cohort FFCD-ANABASE

经放疗或放化疗后肛管鳞状细胞癌的挽救性腹会阴联合切除术:法国前瞻性队列FFCD-ANABASE分析

2025-07-280
PRE
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial

FOLFIRINOX或FOLFOX用于局部晚期或转移性小肠腺癌:PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA II期随机试验

2025-07-280
OAAI
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial

合并用药对早期结直肠癌患者复发、生存和化疗耐受性的影响——PETACC 8试验的事后分析

2025-07-120
OA
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

循环肿瘤DNA强烈预测化疗联合免疫检查点抑制剂在晚期胃食管腺癌患者中的疗效

2025-04-240
OA
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

TFOX与FOLFOX在HER2阴性晚期胃或胃食管结合部腺癌患者一线治疗中的比较(PRODIGE 51-FFCD-GASTFOX):一项开放标签、多中心、随机、III期临床试验

2025-04-230
PRE
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study

直肠腺癌伴同步转移患者的诱导三联化疗:一项AGEO-FFCD研究

2025-01-010
OAAI
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer
2025-01-010
OAAI
Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE
2025-01-010
PRE
Efficacy and Toxicity of (Chemo)Radiation Therapy in HIV plus Patients with Squamous Cell Anal Cancer, a Subgroup Analysis of the National Multicenter Cohort FFCD-ANABASE
2024-11-010
PRE
PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA:一项II期随机试验,旨在评估mFOLFIRINOX和mFOLFOX方案在局部晚期或转移性小肠腺癌治疗中的效果。

2024-09-010
PRE